SAMSRITA LABS LIMITED (SAMSRITA.BO)
INR 22.97
(4.98%)
INR 22.97
(4.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 32.93 Million INR | 8.24% |
| 2022 | 30.42 Million INR | -22.01% |
| 2021 | 39.01 Million INR | -28.08% |
| 2020 | 54.24 Million INR | -56.33% |
| 2019 | 124.23 Million INR | 24.59% |
| 2018 | 99.71 Million INR | 34.68% |
| 2017 | 74.03 Million INR | 2.44% |
| 2016 | 72.27 Million INR | 315.88% |
| 2015 | 17.37 Million INR | -31.52% |
| 2014 | 25.37 Million INR | 433.57% |
| 2013 | 4.75 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -123.43 Million INR | -474.77% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 32.93 Million INR | 0.0% |
| 2023 FY | 32.93 Million INR | 8.24% |
| 2023 Q2 | 31.75 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 40.1 Million INR | 0.0% |
| 2022 Q4 | 30.42 Million INR | 0.0% |
| 2022 FY | 30.42 Million INR | -22.01% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 39.01 Million INR | -28.08% |
| 2021 Q4 | 39.01 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 136.03 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 FY | 54.24 Million INR | -56.33% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 130.43 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 134.51 Million INR | 0.0% |
| 2019 Q2 | 112.41 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 124.23 Million INR | 24.59% |
| 2019 Q1 | - INR | 0.0% |
| 2019 Q4 | 122.78 Million INR | 0.0% |
| 2018 FY | 99.71 Million INR | 34.68% |
| 2017 FY | 74.03 Million INR | 2.44% |
| 2016 Q2 | 69 Thousand INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 72.27 Million INR | 0.0% |
| 2016 FY | 72.27 Million INR | 315.88% |
| 2015 FY | 17.37 Million INR | -31.52% |
| 2014 FY | 25.37 Million INR | 433.57% |
| 2014 Q1 | - INR | 0.0% |
| 2014 Q4 | 25.37 Million INR | 0.0% |
| 2013 FY | 4.75 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 1.36 Billion INR | 97.589% |
| Biocon Limited | 307.95 Billion INR | 99.989% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | 98.458% |
| Concord Biotech Limited | 1.74 Billion INR | 98.108% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | 99.917% |
| FERMENTA BIOTECH LIMITED | 2.62 Billion INR | 98.746% |
| GENOMIC VALLEY BIOTECH LIMITED | 7.91 Million INR | -316.05% |
| Lyka Labs Limited | 884.58 Million INR | 96.277% |
| Panacea Biotec Limited | 4.02 Billion INR | 99.181% |
| Servoteach Industries Limited | 5275.00 INR | -624260.19% |
| SMS Lifesciences India Limited | 1.96 Billion INR | 98.327% |
| Supriya Lifescience Limited | 1.05 Billion INR | 96.889% |
| Syngene International Limited | 18.93 Billion INR | 99.826% |
| TAKE Solutions Limited | 969.78 Million INR | 96.604% |
| Titan Biotech Limited | 231.28 Million INR | 85.76% |
| Transgene Biotek Limited | 393.11 Million INR | 91.622% |
| Vanta Bioscience Limited | 724.23 Million INR | 95.452% |